Inhibikase Therapeutics (IKT) Total Debt (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Total Debt for 6 consecutive years, with $37944.0 as the latest value for Q2 2025.
- On a quarterly basis, Total Debt fell 75.07% to $37944.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $37944.0, a 75.07% decrease, with the full-year FY2024 number at $110517.0, down 26.37% from a year prior.
- Total Debt was $37944.0 for Q2 2025 at Inhibikase Therapeutics, down from $74772.0 in the prior quarter.
- In the past five years, Total Debt ranged from a high of $248911.0 in Q1 2021 to a low of $37944.0 in Q2 2025.
- A 5-year average of $146537.4 and a median of $147433.5 in 2023 define the central range for Total Debt.
- Peak YoY movement for Total Debt: rose 4.92% in 2023, then tumbled 75.07% in 2025.
- Inhibikase Therapeutics' Total Debt stood at $248911.0 in 2021, then tumbled by 41.41% to $145836.0 in 2022, then grew by 2.92% to $150095.0 in 2023, then dropped by 26.37% to $110517.0 in 2024, then tumbled by 65.67% to $37944.0 in 2025.
- Per Business Quant, the three most recent readings for IKT's Total Debt are $37944.0 (Q2 2025), $74772.0 (Q1 2025), and $110517.0 (Q4 2024).